Medication info

Pfizer Leucovorin Injection 15mg (Calcium Leucovorin)

Prescription medication
Ingredient · strength
Calcium Folinate›16.2mg / 1 ampoule
Manufacturer / importer
Pfizer Pharmaceuticals Korea Limited
Appearance
A clear yellow injection solution filled in a brown ampoule
Packaging
2 milliliters X 5 ampoules
Approval status
Active

MFDS item code 199907234 · Notified 1999.11.15 · Insurance code 648902951

Summary

Main use
Combination treatment with 5-FU for advanced colorectal cancer; mitigation of toxicity from folate metabolism antagonists
Who uses it
Adults
Adult dosage
(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur at the usual dose of methotrexate (a folic acid antagonist), administer 6-12mg of folinate intramuscularly per dose 4 times daily, every 6 hours. In the event of methotrexate overdose, administer the same amount as the methotrexate dose given. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate intravenously per dose every 3 hours for 9 doses, followed by intravenous or intramuscular administration every 6 hours for 8 doses. If severe adverse reactions thought to be caused by methotrexate occur, increase the dose and extend the duration of administration. 3. Concomitant administration with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Choose one of the two regimens. 1) Slowly administer calcium folinate 200mg/㎡ intravenously over at least 3 minutes, followed by intravenous administration of 5-FU 370mg/㎡. 2) Administer calcium folinate 20mg/㎡ intravenously, followed by intravenous administration of 5-FU 425mg/㎡. Do not administer these simultaneously, as a precipitate of 5-FU and folinate may form. Continue the above treatment for 5 days and repeat it at 4-week intervals. (Tablet) In the event of an overdose of a folic acid antagonist (e.g., methotrexate), administer folinate 10mg per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) until the serum methotrexate concentration is 10-8M/L or less. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If the serum creatinine concentration 24 hours later has increased by 50% compared with before methotrexate administration, or if the serum methotrexate concentration 24 hours later is 5X10-6M/L or higher, administer a high dose of calcium folinate. Oral doses of 25mg or more are not recommended; administer parenterally. Administer fluids to maintain urine output of 1800-2000mL/㎡ daily, while alkalinizing the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate concentration is 5×10-8M/L(0.05μM/L).

Ingredients

Importer
Pfizer Pharmaceuticals Korea Limited

Efficacy & effects

Combination treatment with 5-FU for advanced colorectal cancer; mitigation of toxicity from folate metabolism antagonists

  • Toxicity from folate antagonists
View approved original text

This medication shows effectiveness when administered with 5-Fluorouracil (5-FU), which is used in the treatment of advanced colorectal cancer, while reducing the toxicity caused by folate antagonists. In other words, it helps lessen side effects that may occur during 5-FU treatment and enhances treatment efficacy. Therefore, it is used to alleviate side effects and improve treatment effects in patients with advanced colorectal cancer.

Dosage and Administration

Adult dosage

(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur at the usual dose of methotrexate (a folic acid antagonist), administer 6-12mg of folinate intramuscularly per dose 4 times daily, every 6 hours. In the event of methotrexate overdose, administer the same amount as the methotrexate dose given. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate intravenously per dose every 3 hours for 9 doses, followed by intravenous or intramuscular administration every 6 hours for 8 doses. If severe adverse reactions thought to be caused by methotrexate occur, increase the dose and extend the duration of administration. 3. Concomitant administration with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Choose one of the two regimens. 1) Slowly administer calcium folinate 200mg/㎡ intravenously over at least 3 minutes, followed by intravenous administration of 5-FU 370mg/㎡. 2) Administer calcium folinate 20mg/㎡ intravenously, followed by intravenous administration of 5-FU 425mg/㎡. Do not administer these simultaneously, as a precipitate of 5-FU and folinate may form. Continue the above treatment for 5 days and repeat it at 4-week intervals. (Tablet) In the event of an overdose of a folic acid antagonist (e.g., methotrexate), administer folinate 10mg per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) until the serum methotrexate concentration is 10-8M/L or less. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If the serum creatinine concentration 24 hours later has increased by 50% compared with before methotrexate administration, or if the serum methotrexate concentration 24 hours later is 5X10-6M/L or higher, administer a high dose of calcium folinate. Oral doses of 25mg or more are not recommended; administer parenterally. Administer fluids to maintain urine output of 1800-2000mL/㎡ daily, while alkalinizing the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate concentration is 5×10-8M/L(0.05μM/L).

Precautions

This medication is not suitable for treating pernicious anemia or megaloblastic anemia caused by vitamin B12 deficiency. Neurological symptoms may improve even if hematological status remains compromised, so caution is needed. In the case of injectable forms, be very careful when opening the ampoule as glass fragments may enter, especially when used in children or the elderly. Pregnant or breastfeeding women should not use this drug in conjunction with 5-FU, and caution should be exercised even when administered alone. This drug may cause allergic reactions such as urticaria or anaphylaxis, so any unusual symptoms must be reported to medical personnel immediately. Pain or temporary discomfort may occur at the injection site, and rarely fever or central nervous system symptoms (paralysis, agitation, depression) may appear. When administered with 5-FU, side effects such as diarrhea, skin reactions, or mucositis may occur, necessitating dosage adjustments of 5-FU based on symptoms. This drug should be used in conjunction with methotrexate, and the plasma concentration of methotrexate should be regularly monitored to assess treatment efficacy and toxicity reduction. In cases of renal impairment or excessive fluid retention, drug excretion may be delayed, and dosage adjustments may be required. This medication uses a transporter similar to methotrexate, so patients resistant to methotrexate may also be resistant to this drug. In cases of vomiting or difficulty absorbing orally, it is preferable to administer this drug intravenously rather than orally. In patients with central nervous system tumors, repeated administration may lead to drug accumulation, diminishing anticancer effects, so avoid overdose. This medication is not used for the treatment of macrocytic anemia caused by specific DNA synthesis inhibitors. Additionally, this drug may increase the metabolism of enzymes in the liver, potentially lowering serum concentrations of some anticonvulsants, thus monitoring plasma concentration and dosage adjustments are necessary in pediatric patients at risk for seizures. It may increase the efficacy and side effects of 5-FU, so caution is necessary when co-administering. Pregnant and breastfeeding women should administer this drug considering the established safety for fetuses and newborns, weighing the needs against the risks. Elderly individuals may have an increased risk of side effects due to diminished bodily functions and should be monitored carefully. This medication is contraindicated for epidural administration, and caution should be taken not to inject too quickly due to its calcium content during intravenous administration. Store out of reach of children and keep in its original container to prevent misuse or degradation of quality.

Side effects

  • Anaphylactic reactions
  • urticaria
  • vascular pains
  • transient pains
  • fever
  • paralysis disorders
  • agitation
  • depression
  • diarrhea
  • skin reactions
Show 6 more
  • skin dryness
  • stomatitis
  • conjunctivitis
  • mucositis
  • mild hematotoxicity
  • leukopenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to avoid contact with air and kept in a cool place between 2 and 8 degrees Celsius. It is also important to avoid direct sunlight, as light may degrade its efficacy.

Appearance and packaging

Appearance

A clear yellow injection solution filled in a brown ampoule

Package unit

2 milliliters X 5 ampoules

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.